Trial Profile
A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TML
- Sponsors Roche
- 09 Mar 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
- 18 Jan 2014 Results of a post-hoc analysis based on KRAS status and first-line therapy presented at the 2014 Gastrointestinal Cancers Symposium.
- 04 Jun 2013 Patterns of disease progression and outcomes presented at the 49th Annual Meeting of the American Society of Clinical Oncology.